Skip to Content
Merck
  • A retrospective two-center study of antiepileptic prophylaxis in patients with surgically treated high-grade gliomas.

A retrospective two-center study of antiepileptic prophylaxis in patients with surgically treated high-grade gliomas.

Neurology India (2013-05-07)
Diego Garbossa, Pier Paolo Panciani, Romina Angeleri, Luigi Battaglia, Fulvio Tartara, Marco Ajello, Alessandro Agnoletti, Pietro Versari, Alessandro Ducati, Marco Fontanella, Giannantonio Spena
ABSTRACT

The effectiveness of antiepileptic prophylaxis in patients with newly diagnosed high-grade glioma is debated. Craniotomy, surgical manipulation and bleeding are believed to favor the onset of seizures and, therefore, perioperative antiepileptic drugs (AEDs) are generally used. Nevertheless, evidence to initiate preoperative AED prophylaxis are weak. Aim of this paper was to evaluate the need for AED prophylaxis in surgically-treated malignant glioma patients without history of seizures. We conducted a retrospective, two-center cohort study to assess the effectiveness of preoperative AED prophylaxis. Patients were divided in two groups: one with AED preoperative administration and the other without. Because of its non-hepatic metabolism, levetiracetam (LEV) was chosen. Logistic regression models were used to investigate the odds ratio for each group. The explanatory variables included the treatment received, sex, age, and site of lesion. The outcome measure of successful LEV prophylaxis was seizure vs. no seizure post-operatively, at three and six months after surgery. Our results showed that LEV prophylaxis was not a significant predictor of seizure occurrence, although the regression coefficient indicated a slight reduction in seizure risk following LEV administration. Patient's age was a significant predictor of seizure occurrence. Younger patients had a higher risk of seizure in the six months post-surgery. We conclude that AEDs prophylaxis does not provide a substantial benefit to surgically treated high-grade glioma patients and should not be administered routinely. Further investigations are required to detect subgroups of patients at higher risk of developing seizures in order to selectively administer AED.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Piracetam
Levetiracetam impurity D, European Pharmacopoeia (EP) Reference Standard
Levetiracetam, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Levetiracetam, ≥98% (HPLC)
Supelco
Levetiracetam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®